Senseonics Holdings, Inc. (SENS)

Senseonics Holdings, Inc. (SENS) stock price has experienced notable events over the past six months. From April 10, 2025, to April 9, 2026, the share price declined, but there have been recent upward shifts influenced by positive real-world data and insider buying activity. The company reported strong financial results for the fourth quarter and full year 2025. Fourth-quarter 2025 revenue increased by 72% year-over-year to $14.3 million, and full-year 2025 revenue grew by 57% year-over-year to $35.3 million. This growth was largely driven by the successful transition to a fully integrated commercial model. The company also received CE Mark approval for Eversense 365 in Europe and launched its first Eversense 365 Automated Insulin Delivery (AID) system integration with twiist in the U.S. Insider buying by the CEO and a board member occurred in March 2026, following earlier insider purchases in November 2025.

Demand for Senseonics Holdings, Inc.'s products and services exhibits seasonality. The company anticipates that its revenue will be weighted towards the second half of 2026. This seasonality is influenced by the timing of annual reorders for its continuous glucose monitoring systems.

Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing continuous glucose monitoring (CGM) systems for individuals with diabetes. The company's primary product line, Eversense, includes implantable CGM systems such as Eversense, Eversense XL, Eversense E3, and Eversense 365. These systems feature a small sensor inserted under the skin, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management. The Eversense E3 system provides continuous glucose monitoring for up to 180 days, while the Eversense 365 system extends this to 365 days. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.

Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, United States. The company operates in the United States and internationally, with the majority of its revenue generated from the U.S. market. Eversense 365 has received CE Mark approval, enabling its commercialization across the European Union, with planned launches in countries such as Germany, Italy, Spain, and Sweden.

In the past year, Senseonics Holdings, Inc.'s brand reputation has seen a cautiously positive shift among analysts and investors, moving beyond previous commercialization uncertainties. This improvement is partly attributed to the presentation of positive real-world evidence demonstrating the sustained performance of the Eversense 365 CGM system over one year. The company's direct-to-consumer marketing efforts have been successful, contributing to a 103% increase in new patient growth in the U.S. in 2025 compared to 2024. The expansion of its Eon Care inserter network and the integration of Eversense 365 with automated insulin delivery systems like twiist have also positively impacted its standing in the diabetes care community.

Major institutional owners of Senseonics Holdings, Inc. include Vanguard Group Inc, BlackRock, Inc., Geode Capital Management, Llc, Hood River Capital Management LLC, Goldman Sachs Group Inc, Masters Capital Management Llc, Charles Schwab Investment Management Inc, UBS Group AG, Parkman Healthcare Partners LLC, Schonfeld Strategic Advisors LLC, Point72 Asset Management, L.P., and State Street Global Advisors, Inc. As of April 9, 2026, these institutions collectively held 6,758,687 shares. Individual insiders, including the CEO Timothy Goodnow and board member Douglas Roeder, have also made significant share purchases in the past six months.